LOS ANGELES, CA, May 09, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution agreement with Plagens Medical Consultants for the distribution of SofPulse™, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling.
SofPulse™ is the Company's FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. SofPulse™ is an easy-to-place, non-invasive device delivering targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery. tMCT is an innovative process using proprietary technology to reduce pain and swelling. The therapy is non-invasive and non-pharmacologic, with no known side effects and no potential for overdose or dependency. SofPulse™ has been used effectively and studied extensively in soft tissue post-operative management. The low levels of microcurrent are completely safe and, in fact, are 1000 times lower than those emitted by a mobile phone.
The Company's Electroceutical™ Therapy has been evaluated in 5 randomized, double-blind controlled clinical trials demonstrating:
- 300% decrease in mean pain scores at 5 hours post-surgery;
- 2.2-fold reduction in narcotic use post-surgery in active users; and
- 275% lower mean IL-1 beta (inflammatory biomarker) in the wound exudates of active users following surgery
Endonovo's non-invasive pain relief therapy, SofPulse®, represents a low-cost, drug free solution to the over use of opioids following surgical procedures. Following surgery, many patients will head home with prescriptions for 30 or more opioid painkillers, which is enough to trigger addiction. However, the American Society of Anesthesiologists recommends using prescription painkillers sparingly, if at all, after surgery. Post-surgical prescription practices have played a role in the opioid epidemic and despite the risk of dependence, many surgery patients receive opioid prescriptions for a month's supply or more. Furthermore, about 6 percent of surgery patients are still using opioid painkillers three months or longer after their surgery, according to a study published last year in JAMA Surgery.
Non-invasive electrotherapies, such as Endonovo's SofPulse®, are believed to modulate pain signaling through activation of peripheral endogenous opioids and opioid receptors; making these non-pharmacological devices an extremely safe and economical alternative to prescription painkillers.
Alan Collier, Endonovo Chief Executive Officer, stated, “We are pleased to establish this partnership with Plagens Medical Consultants and I look forward to collaborating with their team to bring SofPulse to a national level. Plagens is a great partner for the SofPulse brand, possessing the scale, infrastructure, reputation, clinical experience and complementary product portfolio to make SofPulse a market leader in post-surgical pain management, recovery and rehabilitation. We are excited Plagens recognized the quality, robustness, innovation and design quality of SofPulse."
"Plagens Medical Consultants, a medical device company established in 1978 and with over 65 years of combined leadership experience, is proud to announce its partnership with Endonovo. Plagens is confident Endonovo's SofPulse will effectively address the opioid problems associated with orthopedic injuries and surgical recovery while providing a non-pharmaceutical option for patients. The feedback we have received on SofPulse from Physicians and other providers has been remarkable. Plagens is anxious to bring this to market in Michigan and the surrounding Great Lakes area." - Jason Walters, Senior Shareholder / Partner, Plagens Medical Consultants.
The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed.
About Plagens Medical Consultants
Since 1978, Plagens has specialized in supplying a diverse range of musculoskeletal devices to hospitals and healthcare providers in Michigan and the surrounding Great Lakes area. In 2013, Plagens expanded its distribution to include products for surgical and non-surgical pain management as well as recovery and rehabilitation. www.plagens.com
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresseses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) dDisorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device , SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticalss™ addresses chronic kidney disease, liver diseasenon-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
CONTACT: Investor Relations Contact: Endonovo Therapeutics, Inc. Mr. Andrew Barwicki 516-662-9461 Andrew@barwicki.com www.endonovo.com